Hod Ha-sharon, Israel
Study Comparing Tapinarof Cream 1% to VTAMA ® (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis
To compare the safety of Test, Reference, and Placebo treatments in patients with Plaque Psoriasis. Patients in this randomized, double-blind, three-arm, placebo controlled, parallel-design, multi-site study will be randomly assigned in a 2:2:1 ratio to treatment with the test product, reference product or placebo control, respectively.
Phase
3Span
50 weeksSponsor
Teva Pharmaceuticals USALouisville, Kentucky
Recruiting
Healthy Volunteers
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose. There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period. Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.
Phase
3Span
147 weeksSponsor
Celldex TherapeuticsLouisville, Kentucky
Recruiting
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Phase
3Span
97 weeksSponsor
Alumis IncLouisville, Kentucky
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects with Non-segmental Vitiligo.
Phase
2Span
87 weeksSponsor
Vyne Therapeutics Inc.Louisville, Kentucky
Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
Phase
3Span
109 weeksSponsor
MoonLake Immunotherapeutics AGLouisville, Kentucky
Recruiting
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Phase
N/ASpan
504 weeksSponsor
argenxLouisville, Kentucky
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Phase
3Span
298 weeksSponsor
Shanghai Junshi Bioscience Co., Ltd.Louisville, Kentucky
Recruiting
CERENOVUS Neurothrombectomy Devices Registry
The objective of this study are to separately assess the effectiveness of the CERENOVUS neurothrombectomy devices (EmboTrap® Revascularization Device, and Large Bore Catheter/EMBOVAC Aspiration Catheter) in a real-world setting, as well as to explore correlations between patient comorbidities, clot characteristics, revascularization rates, and clinical outcomes..
Phase
N/ASpan
314 weeksSponsor
Cerenovus, Part of DePuy Synthes Products, Inc.Louisville, Kentucky
Recruiting
Safety and Efficacy of VDPHL01 in Males With AGA
Phase
3Span
90 weeksSponsor
Veradermics, Inc.Louisville, Kentucky
Recruiting
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
Phase
N/ASpan
289 weeksSponsor
University of MichiganLouisville, Kentucky
Recruiting